Medacta Group（MOVE）株式概要
メダクタ・グループSAは、中南米、北米、アジア太平洋、中東・アフリカで整形外科・神経外科用医療機器の開発・製造・販売を行っている。 詳細
報酬
リスク分析
リスクチェックの結果、MOVE 、リスクは検出されなかった。
MOVE Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Medacta Group SA 競合他社
価格と性能
| 過去の株価 | |
|---|---|
| 現在の株価 | CHF 131.60 |
| 52週高値 | CHF 177.20 |
| 52週安値 | CHF 128.20 |
| ベータ | 0.98 |
| 1ヶ月の変化 | -7.06% |
| 3ヶ月変化 | -6.00% |
| 1年変化 | -12.27% |
| 3年間の変化 | 6.47% |
| 5年間の変化 | 1.86% |
| IPOからの変化 | 36.94% |
最新ニュース
分析記事 • 15h
If EPS Growth Is Important To You, Medacta Group (VTX:MOVE) Presents An Opportunity
The excitement of investing in a company that can reverse its fortunes is a big draw for some speculators, so even...
ナラティブ更新 • Jun 23
MOVE: Insider Alignment And Earnings Quality Will Support Future Upside Potential
Analysts have slightly adjusted their CHF fair value estimate for Medacta Group to CHF 179.08, reflecting updated assumptions for the discount rate, revenue growth, profit margin and future P/E multiple. What's in the News for Medacta Group Medacta Group has been highlighted for consistent earnings per share growth of 27% per year over the last three years, alongside revenue growth of 16% and steady EBIT margins, according to recent coverage from Simply Wall St. Insiders at Medacta Group are reported to hold around 70% of the company, which closely aligns management and shareholder interests, based on the same Simply Wall St analysis.分析記事 • Jun 07
What Is Medacta Group SA's (VTX:MOVE) Share Price Doing?
Medacta Group SA ( VTX:MOVE ), is not the largest company out there, but it saw significant share price movement during...ナラティブ更新 • Jun 05
MOVE: Earnings Outlook And Dividend Will Support Future Upside Potential
Analysts have nudged their price target on Medacta Group slightly lower to CHF 179.08 from CHF 179.46, reflecting updated fair value assumptions and a modestly lower future P/E multiple, while keeping revenue growth and profit margin expectations essentially unchanged. What's in the News Medacta has been selected to join an international research project focused on recreating dinosaurs from preserved DNA, working alongside Resurgence Biotechnology, ETH Zurich, World Regenesis Lab and the Natural Science Museum London (source: company client announcement).Recent updates
分析記事 • 15h
If EPS Growth Is Important To You, Medacta Group (VTX:MOVE) Presents An Opportunity
The excitement of investing in a company that can reverse its fortunes is a big draw for some speculators, so even...ナラティブ更新 • Jun 23
MOVE: Insider Alignment And Earnings Quality Will Support Future Upside Potential
Analysts have slightly adjusted their CHF fair value estimate for Medacta Group to CHF 179.08, reflecting updated assumptions for the discount rate, revenue growth, profit margin and future P/E multiple. What's in the News for Medacta Group Medacta Group has been highlighted for consistent earnings per share growth of 27% per year over the last three years, alongside revenue growth of 16% and steady EBIT margins, according to recent coverage from Simply Wall St. Insiders at Medacta Group are reported to hold around 70% of the company, which closely aligns management and shareholder interests, based on the same Simply Wall St analysis.分析記事 • Jun 07
What Is Medacta Group SA's (VTX:MOVE) Share Price Doing?
Medacta Group SA ( VTX:MOVE ), is not the largest company out there, but it saw significant share price movement during...ナラティブ更新 • Jun 05
MOVE: Earnings Outlook And Dividend Will Support Future Upside Potential
Analysts have nudged their price target on Medacta Group slightly lower to CHF 179.08 from CHF 179.46, reflecting updated fair value assumptions and a modestly lower future P/E multiple, while keeping revenue growth and profit margin expectations essentially unchanged. What's in the News Medacta has been selected to join an international research project focused on recreating dinosaurs from preserved DNA, working alongside Resurgence Biotechnology, ETH Zurich, World Regenesis Lab and the Natural Science Museum London (source: company client announcement).ナラティブ更新 • Apr 25
MOVE: Earnings Outlook And Dividend Will Drive Future Upside Potential
Analysts have nudged their price target for Medacta Group slightly lower to CHF 179 from about CHF 181. This reflects updated assumptions for fair value, discount rate, revenue growth, profit margin and future P/E that are broadly consistent with previous expectations.ナラティブ更新 • Apr 11
MOVE: Earnings Outlook And Dividend Will Drive Further Upside Potential
Analysts have nudged their price target for Medacta Group slightly higher to CHF181.43 from CHF180.07, reflecting updated assumptions around fair value, discount rate, revenue growth, profit margins, and future P/E expectations. What's in the News Medacta has joined an international research project focused on recreating dinosaurs from preserved DNA, working with partners including Resurgence Biotechnology, ETH Zurich, World Regenesis Lab and the Natural History Museum in London.ナラティブ更新 • Mar 28
MOVE: Earnings Outlook And Dividend Will Support Further Upside Potential
Analysts have raised their price target on Medacta Group to CHF 180.07 from CHF 177.36, citing updated assumptions for the discount rate, revenue growth, profit margin, and future P/E. What's in the News Company issued earnings guidance for 2026, targeting revenue growth in a range of 10% to 14% in constant currency (Key Developments).ナラティブ更新 • Mar 12
MOVE: Slightly Higher Return Hurdle Will Still Support Future Upside
The analyst price target for Medacta Group has been adjusted slightly lower to reflect a revised fair value of about CHF 177.36, with analysts pointing to modest tweaks in the discount rate, revenue growth, profit margin and future P/E assumptions. Valuation Changes Fair Value: CHF 177.36, slightly lower than the prior estimate of CHF 178.87.ナラティブ更新 • Feb 26
MOVE: Slightly Higher Return Hurdle And Lower P/E Will Still Support Upside
Analysts have maintained their CHF 178.87 price target for Medacta Group, with the slight adjustment in discount rate and lower assumed future P/E multiple reflecting a more cautious stance on valuation assumptions while keeping the overall target level unchanged. Valuation Changes Fair Value: CHF 178.87 remains unchanged, indicating no adjustment to the overall fair value estimate.ナラティブ更新 • Feb 10
MOVE: Higher Growth Assumptions And Richer P/E Will Support Gradual Upside
Analysts have nudged their price target for Medacta Group slightly higher, to €178.87 from €178.20, reflecting updated views on discount rates, revenue growth, profit margins, and the future P/E multiple. Valuation Changes Fair Value: updated slightly higher from €178.20 to €178.87.ナラティブ更新 • Jan 25
MOVE: Modest Assumption Tweaks And Firm Margins Will Underpin Gradual Performance
Analysts have raised their price target on Medacta Group to approximately CHF 178 from about CHF 167, citing slightly adjusted assumptions around the discount rate, revenue growth, profit margin, and a future P/E of roughly 35x in their updated models. Valuation Changes Fair Value: Updated model fair value moves from about CHF 166.69 to roughly CHF 178.20 per share.分析記事 • Jan 21
Subdued Growth No Barrier To Medacta Group SA's (VTX:MOVE) Price
With a price-to-earnings (or "P/E") ratio of 38.5x Medacta Group SA ( VTX:MOVE ) may be sending very bearish signals at...ナラティブ更新 • Jan 08
MOVE: Steady Margins And Refined Assumptions Will Support Gradual Performance
Analysts have nudged their price target on Medacta Group slightly higher to reflect a modestly lower discount rate and a small refinement in assumed future P/E. This suggests a fine tuning of their valuation rather than a major shift in view.分析記事 • Dec 30
Is It Time To Consider Buying Medacta Group SA (VTX:MOVE)?
While Medacta Group SA ( VTX:MOVE ) might not have the largest market cap around , it saw a double-digit share price...ナラティブ更新 • Dec 25
MOVE: Steady Margins And Fair Pricing Will Support Gradual Performance
Narrative Update on Medacta Group Analysts have modestly raised their price target on Medacta Group, citing a slightly higher long term discount rate and marginally richer future earnings multiple expectations that together point to a fair value of approximately CHF 166.70 per share. Valuation Changes Fair Value Estimate, unchanged at approximately CHF 166.70 per share, indicating no revision to the central valuation outcome.ナラティブ更新 • Dec 11
MOVE: Lower Risk And Steady Margins Will Support Gradual Performance Outlook
Analysts have modestly raised their price target on Medacta Group to approximately CHF 166.70 from around CHF 164.40, reflecting slightly lower perceived risk, a marginally stronger long term profit margin outlook, and a small upward revision to anticipated future valuation multiples. Valuation Changes Fair Value has risen slightly from approximately CHF 164.40 to about CHF 166.70, implying a modest increase in the assessed intrinsic value.ナラティブ更新 • Nov 26
MOVE: Stable Earnings Guidance And Margins Will Support Measured Performance Outlook
Analysts have maintained their price target for Medacta Group at CHF 164.40. They cite steady profit margin expectations and a stable outlook for revenue growth, despite minor adjustments to the discount rate.ナラティブ更新 • Nov 10
MOVE: Revenue Will Hold Steady as Earnings Guidance Signals Further Upside
Narrative Update: Medacta Group Price Target Adjustment Analysts have slightly lowered their fair value estimate for Medacta Group from CHF164.46 to CHF164.40, citing minor model updates that reflect changes in discount rate assumptions. What's in the News Medacta Group SA confirmed its earnings guidance for 2025, targeting revenue growth of 16% to 18% in constant currency, subject to unforeseen events (Company Guidance).分析記事 • Nov 08
Medacta Group (VTX:MOVE) Is Looking To Continue Growing Its Returns On Capital
Finding a business that has the potential to grow substantially is not easy, but it is possible if we look at a few key...ナラティブ更新 • Oct 27
Earnings Guidance And Updated Outlook Will Drive Expansion Across New Markets
Analysts have raised their price target for Medacta Group from CHF156.91 to CHF164.46, citing modest adjustments to growth and margin expectations as reflected in updated forecasts. What's in the News Medacta Group SA confirmed its earnings guidance for 2025, targeting revenue growth in the range of 16% to 18% in constant currency, subject to unforeseen events (Key Developments).分析記事 • Oct 21
Does Medacta Group (VTX:MOVE) Have A Healthy Balance Sheet?
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...分析記事 • Oct 01
Investor Optimism Abounds Medacta Group SA (VTX:MOVE) But Growth Is Lacking
When close to half the companies in Switzerland have price-to-earnings ratios (or "P/E's") below 19x, you may consider...分析記事 • Sep 13
Medacta Group's (VTX:MOVE) Solid Profits Have Weak Fundamentals
Medacta Group SA ( VTX:MOVE ) just reported some strong earnings, and the market reacted accordingly with a healthy...分析記事 • Sep 12
Should You Investigate Medacta Group SA (VTX:MOVE) At CHF150?
While Medacta Group SA ( VTX:MOVE ) might not have the largest market cap around , it saw a decent share price growth...分析記事 • Aug 29
Estimating The Fair Value Of Medacta Group SA (VTX:MOVE)
Key Insights Medacta Group's estimated fair value is CHF129 based on 2 Stage Free Cash Flow to Equity Current share...分析記事 • Aug 01
Medacta Group (VTX:MOVE) Has Some Way To Go To Become A Multi-Bagger
If you're not sure where to start when looking for the next multi-bagger, there are a few key trends you should keep an...分析記事 • Jun 24
Do Medacta Group's (VTX:MOVE) Earnings Warrant Your Attention?
It's common for many investors, especially those who are inexperienced, to buy shares in companies with a good story...分析記事 • May 24
What Does Medacta Group SA's (VTX:MOVE) Share Price Indicate?
Medacta Group SA ( VTX:MOVE ), is not the largest company out there, but it saw a significant share price rise of 23...分析記事 • May 10
Market Participants Recognise Medacta Group SA's (VTX:MOVE) Earnings Pushing Shares 26% Higher
Medacta Group SA ( VTX:MOVE ) shareholders would be excited to see that the share price has had a great month, posting...分析記事 • May 01
Medacta Group SA's (VTX:MOVE) CEO Compensation Looks Acceptable To Us And Here's Why
Key Insights Medacta Group's Annual General Meeting to take place on 7th of May Total pay for CEO Francesco Siccardi...分析記事 • Apr 24
Here's Why Medacta Group (VTX:MOVE) Can Manage Its Debt Responsibly
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...分析記事 • Apr 10
Return Trends At Medacta Group (VTX:MOVE) Aren't Appealing
Did you know there are some financial metrics that can provide clues of a potential multi-bagger? In a perfect world...分析記事 • Mar 28
Medacta Group SA (VTX:MOVE) Yearly Results: Here's What Analysts Are Forecasting For This Year
The full-year results for Medacta Group SA ( VTX:MOVE ) were released last week, making it a good time to revisit its...分析記事 • Feb 13
Medacta Group SA (VTX:MOVE) Looks Just Right With A 25% Price Jump
Medacta Group SA ( VTX:MOVE ) shareholders would be excited to see that the share price has had a great month, posting...
新しいナラティブ • Feb 09
New Products Like GMK SpheriKA And NextAR Will Strengthen Future Prospects In The Spine Segment
Medacta's innovation in product launches and medical education expansion drives revenue growth, with a strong focus on the Spine segment and ASCs.分析記事 • Jan 06
Returns On Capital Signal Tricky Times Ahead For Medacta Group (VTX:MOVE)
If you're looking for a multi-bagger, there's a few things to keep an eye out for. Ideally, a business will show two...分析記事 • Nov 22
The Price Is Right For Medacta Group SA (VTX:MOVE)
When close to half the companies in Switzerland have price-to-earnings ratios (or "P/E's") below 19x, you may consider...分析記事 • Oct 14
Is Medacta Group (VTX:MOVE) A Risky Investment?
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...分析記事 • Sep 06
Medacta Group SA (VTX:MOVE) Shares Could Be 32% Above Their Intrinsic Value Estimate
Key Insights Medacta Group's estimated fair value is CHF95.33 based on 2 Stage Free Cash Flow to Equity Current share...分析記事 • Aug 21
What Does Medacta Group SA's (VTX:MOVE) Share Price Indicate?
While Medacta Group SA ( VTX:MOVE ) might not have the largest market cap around , it saw a double-digit share price...分析記事 • Aug 06
Medacta Group (VTX:MOVE) Is Reinvesting At Lower Rates Of Return
If you're looking for a multi-bagger, there's a few things to keep an eye out for. Ideally, a business will show two...分析記事 • Jun 20
Medacta Group SA's (VTX:MOVE) P/E Still Appears To Be Reasonable
With a price-to-earnings (or "P/E") ratio of 54x Medacta Group SA ( VTX:MOVE ) may be sending very bearish signals at...分析記事 • May 01
We Discuss Why Medacta Group SA's (VTX:MOVE) CEO Will Find It Hard To Get A Pay Rise From Shareholders This Year
Key Insights Medacta Group will host its Annual General Meeting on 7th of May Total pay for CEO Francesco Siccardi...分析記事 • Apr 17
Medacta Group (VTX:MOVE) Has A Pretty Healthy Balance Sheet
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...分析記事 • Mar 29
Is Now An Opportune Moment To Examine Medacta Group SA (VTX:MOVE)?
Medacta Group SA ( VTX:MOVE ), might not be a large cap stock, but it received a lot of attention from a substantial...分析記事 • Feb 22
Does Medacta Group (VTX:MOVE) Deserve A Spot On Your Watchlist?
For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...分析記事 • Feb 07
Medacta Group (VTX:MOVE) Will Be Hoping To Turn Its Returns On Capital Around
If you're looking for a multi-bagger, there's a few things to keep an eye out for. Typically, we'll want to notice a...分析記事 • Dec 18
Getting In Cheap On Medacta Group SA (VTX:MOVE) Might Be Difficult
With a price-to-earnings (or "P/E") ratio of 51.3x Medacta Group SA ( VTX:MOVE ) may be sending very bearish signals at...分析記事 • Dec 04
Calculating The Intrinsic Value Of Medacta Group SA (VTX:MOVE)
Key Insights The projected fair value for Medacta Group is CHF109 based on 2 Stage Free Cash Flow to Equity Medacta...分析記事 • Nov 15
Is Now The Time To Look At Buying Medacta Group SA (VTX:MOVE)?
Medacta Group SA ( VTX:MOVE ), might not be a large cap stock, but it saw a double-digit share price rise of over 10...分析記事 • Oct 30
Returns On Capital Signal Tricky Times Ahead For Medacta Group (VTX:MOVE)
There are a few key trends to look for if we want to identify the next multi-bagger. Firstly, we'd want to identify a...分析記事 • Oct 17
If EPS Growth Is Important To You, Medacta Group (VTX:MOVE) Presents An Opportunity
The excitement of investing in a company that can reverse its fortunes is a big draw for some speculators, so even...分析記事 • Sep 29
Is Medacta Group (VTX:MOVE) Using Too Much Debt?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...分析記事 • Aug 11
Calculating The Intrinsic Value Of Medacta Group SA (VTX:MOVE)
Key Insights The projected fair value for Medacta Group is CHF113 based on 2 Stage Free Cash Flow to Equity Medacta...分析記事 • Jul 27
Is Now The Time To Look At Buying Medacta Group SA (VTX:MOVE)?
Medacta Group SA ( VTX:MOVE ), might not be a large cap stock, but it saw a double-digit share price rise of over 10...分析記事 • Jul 03
Be Wary Of Medacta Group (VTX:MOVE) And Its Returns On Capital
If we want to find a stock that could multiply over the long term, what are the underlying trends we should look for...分析記事 • Apr 28
At CHF117, Is It Time To Put Medacta Group SA (VTX:MOVE) On Your Watch List?
Medacta Group SA ( VTX:MOVE ), is not the largest company out there, but it led the SWX gainers with a relatively large...分析記事 • Apr 08
Is Medacta Group (VTX:MOVE) A Risky Investment?
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...分析記事 • Dec 25
Is Now An Opportune Moment To Examine Medacta Group SA (VTX:MOVE)?
Medacta Group SA ( VTX:MOVE ), is not the largest company out there, but it received a lot of attention from a...分析記事 • Dec 09
Capital Allocation Trends At Medacta Group (VTX:MOVE) Aren't Ideal
To find a multi-bagger stock, what are the underlying trends we should look for in a business? In a perfect world, we'd...分析記事 • Nov 09
Does Medacta Group (VTX:MOVE) Have A Healthy Balance Sheet?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...株主還元
| MOVE | CH Medical Equipment | CH 市場 | |
|---|---|---|---|
| 7D | -4.5% | 1.9% | -0.3% |
| 1Y | -12.3% | -8.3% | 18.5% |
業界別リターン: MOVE過去 1 年間で-8.3 % の収益を上げたSwiss Medical Equipment業界を下回りました。
リターン対市場: MOVEは、過去 1 年間で18.5 % のリターンを上げたSwiss市場を下回りました。
価格変動
| MOVE volatility | |
|---|---|
| MOVE Average Weekly Movement | 3.8% |
| Medical Equipment Industry Average Movement | 4.6% |
| Market Average Movement | 4.2% |
| 10% most volatile stocks in CH Market | 7.8% |
| 10% least volatile stocks in CH Market | 2.2% |
安定した株価: MOVE 、 Swiss市場と比較して、過去 3 か月間で大きな価格変動はありませんでした。
時間の経過による変動: MOVEの 週次ボラティリティ ( 4% ) は過去 1 年間安定しています。
会社概要
| 設立 | 従業員 | CEO（最高経営責任者 | ウェブサイト |
|---|---|---|---|
| 1958 | 2,036 | Francesco Siccardi | www.medacta.com |
Medacta Group SAは、中南米、北米、アジア太平洋、中東およびアフリカで整形外科および神経外科用医療機器の開発、製造、販売を行っている。股関節、膝関節、肩関節、人工関節置換術、スポーツ医学、脊椎外科手術に使用される個別化された3Dプランニングツールを提供している。メダクタ・グループSAは1958年に設立され、スイスのカステル・サン・ピエトロに本社を置いている。
Medacta Group SA 基礎のまとめ
| MOVE 基礎統計学 | |
|---|---|
| 時価総額 | CHF 2.65b |
| 収益（TTM） | CHF 89.16m |
| 売上高(TTM) | CHF 638.70m |
29.4x
PER（株価収益率4.1x
P/SレシオMOVE は割高か？
公正価値と評価分析を参照収益と収入
| MOVE 損益計算書（TTM） | |
|---|---|
| 収益 | €683.83m |
| 売上原価 | €225.17m |
| 売上総利益 | €458.66m |
| その他の費用 | €363.20m |
| 収益 | €95.46m |
直近の収益報告
Dec 31, 2025
次回決算日
Sep 09, 2026
| 一株当たり利益（EPS） | 4.79 |
| グロス・マージン | 67.07% |
| 純利益率 | 13.96% |
| 有利子負債／自己資本比率 | 44.9% |
MOVE の長期的なパフォーマンスは？
過去の実績と比較を見る配当金
0.8%
現在の配当利回り25%
配当性向企業分析と財務データの現状
| データ | 最終更新日（UTC時間） |
|---|---|
| 企業分析 | 2026/08/05 20:03 |
| 終値 | 2026/08/05 00:00 |
| 収益 | 2025/12/31 |
| 年間収益 | 2025/12/31 |
データソース
企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。
| パッケージ | データ | タイムフレーム | 米国ソース例 |
|---|---|---|---|
| 会社財務 | 10年 |
| |
| アナリストのコンセンサス予想 | +プラス3年 |
|
|
| 市場価格 | 30年 |
| |
| 所有権 | 10年 |
| |
| マネジメント | 10年 |
| |
| 主な進展 | 10年 |
|
* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。
特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。
分析モデルとスノーフレーク
このレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。
シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。
業界およびセクターの指標
私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。
アナリスト筋
Medacta Group SA 5 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。12
| アナリスト | 機関 |
|---|---|
| Samuel England | Berenberg |
| David Adlington | J.P. Morgan |
| Ilya Burgansky | Research Partners AG |